Sponsor or institution

Clinical trials and research at Incyte Corporation

• 28Clinical trials
• 36Countries

Newest trials

All recruiting trials (28)

• A Phase 3 Test of INCA033989 vs Best Available Therapy for Essential Thrombocythemia with CALR Mutation

  This phase 3 study tests whether INCA033989 can help people with essential thrombocythemia who have a CALR mutation and have already had cytoreductive therapy, compared to the best available treatment.

  Recruiting at 5 sites Phase 3 Incyte Corporation · Birmingham, Alabama and 191 other locations · NCT07623200

• Safety and how the drug behaves in adults with moderate to severe liver impairment

  This study tests the safety and how INCB123667 moves through the body when taken by adults with moderate to severe liver impairment.

  Recruiting at 4 sites Phase 1 Incyte Corporation · Chandler, Arizona and 3 other locations · NCT07559474

• Safety and blood levels of INCB123667 in adults with severe kidney problems

  This study tests whether oral INCB123667 is safe and how it behaves in the body for adults with severe renal impairment or end-stage kidney disease.

  Recruiting at 2 sites Phase 1 Incyte Corporation · Miami Lakes, Florida and 1 other locations · NCT07559396

• Chemotherapy with or without INCB161734 for untreated KRAS G12D metastatic pancreatic cancer

  This will test whether adding the KRAS G12D blocker INCB161734 to standard chemotherapy helps people with newly diagnosed metastatic pancreatic cancer that has a KRAS G12D mutation.

  Recruiting at 131 sites Phase 3 Incyte Corporation · Birmingham, Alabama and 229 other locations · NCT07522073

• INCA036978 for people with myeloproliferative neoplasms

  This Phase 1 study will test whether INCA036978, given alone or with standard therapy, is safe and tolerable for adults with myeloproliferative neoplasms such as myelofibrosis, polycythemia vera, and essential thrombocythemia.

  Recruiting at 18 sites Phase 1 Incyte Corporation · Birmingham, Alabama and 53 other locations · NCT07441694

• First-line treatment with standard chemotherapy and bevacizumab, with or without INCA33890, for metastatic microsatellite-stable colorectal cancer

  This trial will test whether adding a new drug, INCA33890, to standard chemotherapy and bevacizumab helps people with metastatic microsatellite-stable colorectal cancer respond better or live longer.

  Recruiting at 168 sites Phase 3 Incyte Corporation · Mobile, Alabama and 296 other locations · NCT07284849

• INCB123667 versus doctor‑chosen chemotherapy for platinum‑resistant ovarian cancer with cyclin E1 overexpression.

  This trial will see if INCB123667 works better than a doctor‑chosen chemotherapy in people with platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer whose tumors overexpress cyclin E1.

  Recruiting at 51 sites Phase 3 Incyte Corporation · Anchorage, Alaska and 197 other locations · NCT07214779

• Povorcitinib for adolescents with moderate to severe hidradenitis suppurativa

  This trial tests the oral drug povorcitinib in adolescents aged 12–17 with moderate to severe hidradenitis suppurativa to see if it is safe, how the body handles it, and whether it reduces lesions over a 54-week treatment period.

  Recruiting at 28 sites Phase 2 Incyte Corporation · Birmingham, Alabama and 29 other locations · NCT07213973

• INCA036873 for adults with advanced solid tumors and blood cancers.

  This trial will test whether the experimental drug INCA036873 is safe and tolerable in adults with advanced or metastatic solid tumors or certain blood cancers who have already tried standard treatments.

  Recruiting at 19 sites Phase 1 Incyte Corporation · Duarte, California and 21 other locations · NCT07195916

• Axatilimab versus best available therapy for children with chronic graft-versus-host disease after two or more prior treatments

  This trial will test axatilimab against the best available treatments in children aged 2–17 whose chronic graft-versus-host disease has not responded to at least two prior systemic therapies.

  Recruiting at 34 sites Phase 2 Incyte Corporation · Duarte, California and 40 other locations · NCT07124078

• Tafasitamab for adults with primary immune thrombocytopenia or warm autoimmune hemolytic anemia

  This trial will try tafasitamab, an anti‑CD19 antibody, in adults with primary immune thrombocytopenia or warm autoimmune hemolytic anemia to see if it is safe and helps blood counts.

  Recruiting at 39 sites Phase 2 Incyte Corporation · Glendale, Arizona and 38 other locations · NCT07104565

• Maximal-use ruxolitinib cream for adults and teens with hidradenitis suppurativa

  This trial will test whether applying ruxolitinib cream over large skin areas is safe and tolerable in adults and adolescents with hidradenitis suppurativa.

  Recruiting at 16 sites Phase 1 Incyte Corporation · Phoenix, Arizona and 20 other locations · NCT07049575

• INCB123667 for platinum-resistant ovarian cancer with Cyclin E1 overexpression

  This study tests whether INCB123667 can help people with platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer whose tumors overexpress Cyclin E1.

  Recruiting at 74 sites Phase 2 Incyte Corporation · Mobile, Alabama and 73 other locations · NCT07023627

• INCA035784 for people with CALR‑mutated myeloproliferative neoplasms (myelofibrosis or essential thrombocythemia)

  This trial tests whether INCA035784 is safe and tolerable in adults with CALR‑mutated myeloproliferative neoplasms who have already received prior therapies.

  Recruiting at 16 sites Phase 1 Incyte Corporation · Phoenix, Arizona and 25 other locations · NCT07008118

• Continuation of treatment with povorcitinib for previous trial participants

  This study lets people who have already benefited from the medication povorcitinib in a previous trial keep using it to see if it continues to help with their Hidradenitis Suppurativa.

  Recruiting at 247 sites Phase 3 Incyte Corporation · Birmingham, Alabama and 305 other locations · NCT06855498

• Ruxolitinib cream for children 6 to under 12 with nonsegmental vitiligo

  This will test whether ruxolitinib cream can safely produce skin repigmentation in children aged 6 to under 12 with nonsegmental vitiligo.

  Recruiting at 78 sites Phase 3 Incyte Corporation · Buenos Aires and 77 other locations · NCT06804811

• Examining the effects of ruxolitinib cream versus topical corticosteroids in pregnant women with atopic dermatitis

  This study is testing whether using ruxolitinib cream during pregnancy is safer for babies than using regular steroid creams in women with atopic dermatitis.

  Recruiting Incyte Corporation · Morrisville, North Carolina · NCT06627335

• Comparing two treatment regimens for Graft-versus-host Disease after stem cell transplantation

  This study is testing two different treatment plans for adults with Graft-versus-host Disease after stem cell transplantation to see which one works better, especially for those who haven't responded to steroids.

  Recruiting at 30 sites Phase 3 Incyte Corporation · Palo Alto, California and 29 other locations · NCT06615050

• Evaluating axatilimab and corticosteroids for treating chronic graft-versus-host disease

  This study is testing if adding a new drug called axatilimab to standard steroids can help people aged 12 and older who have recently developed moderate to severe chronic graft-versus-host disease feel better.

  Recruiting at 131 sites Phase 3 Incyte Corporation · Birmingham, Alabama and 130 other locations · NCT06585774

• Evaluating Ruxolitinib Cream for Children with Nonsegmental Vitiligo

  This study is testing if ruxolitinib cream can help children with nonsegmental vitiligo regain skin color better than a regular cream.

  Recruiting at 83 sites Phase 3 Incyte Corporation · Birmingham, Alabama and 97 other locations · NCT06548360

• Continued treatment for patients with blood cancers using tafasitamab

  This study is testing if continuing treatment with tafasitamab can help patients with blood cancers who have already seen some improvement from the medication.

  Recruiting at 3 sites Phase 2 Incyte Corporation · Győr and 4 other locations · NCT06465433

• Comparing outcomes for pregnant women with atopic dermatitis using ruxolitinib cream

  This study is trying to see if using ruxolitinib cream during pregnancy is safe for women with mild to moderate atopic dermatitis and their babies compared to those who don’t use it.

  Recruiting Incyte Corporation · Morrisville, North Carolina · NCT06259669

• Evaluating INCB161734 for advanced solid tumors with KRAS G12D mutation

  This study is testing a new drug called INCB161734, alone and with other cancer treatments, to see if it can help people with advanced solid tumors that have a specific KRAS G12D mutation.

  Recruiting at 34 sites Phase 1 Incyte Corporation · Phoenix, Arizona and 33 other locations · NCT06179160

• Evaluating INCA033989 for treating myeloproliferative neoplasms

  This study is testing a new treatment called INCA033989, alone and with another drug, to see if it’s safe and effective for people with myeloproliferative neoplasms who have certain mutations.

  Recruiting at 13 sites Phase 1 Incyte Corporation · Duarte, California and 12 other locations · NCT06034002

• Observational study for patients at risk of chronic graft-versus-host disease

  This study is tracking the health of people who have recently had a stem cell transplant to see if they develop chronic graft-versus-host disease over the next few months.

  Recruiting at 36 sites Incyte Corporation · Birmingham, Alabama and 36 other locations · NCT05919511

• Evaluating the safety of INCA33890 for advanced or metastatic solid tumors

  This study is testing a new drug called INCA33890 to see if it's safe for people with advanced solid tumors who haven't had success with other treatments.

  Recruiting at 36 sites Phase 1 Incyte Corporation · Los Angeles, California and 38 other locations · NCT05836324

• Evaluating INCB000928 for treating Fibrodysplasia Ossificans Progressiva

  This study is testing a new drug called INCB000928 to see if it can help people with Fibrodysplasia Ossificans Progressiva manage their symptoms better.

  Recruiting at 11 sites Phase 2 Incyte Corporation · Rochester, Minnesota and 23 other locations · NCT05090891

• Using ponatinib to treat children with advanced leukemias, lymphomas, or solid tumors

  This study is testing if ponatinib can help children with hard-to-treat leukemias, lymphomas, or solid tumors feel better and have more treatment options.

  Recruiting at 22 sites Phase 1/2 Incyte Corporation · Ghent and 22 other locations · NCT03934372

Quick answers

How many clinical trials run by Incyte Corporation are recruiting right now?

28, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 36 countries. The most sites are in United States (25 trials), Italy (17 trials), Spain (16 trials), United Kingdom (14 trials), Australia (13 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 9, Phase 1: 9, Phase 2: 6, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →